Ontology highlight
ABSTRACT:
SUBMITTER: Rockstroh JK
PROVIDER: S-EPMC5597897 | biostudies-literature | 2017
REPOSITORIES: biostudies-literature
Rockstroh Jürgen K JK Orkin Chloe C Viani Rolando M RM Wyles David D Luetkemeyer Anne F AF Lazzarin Adriano A Soto-Malave Ruth R Nelson Mark R MR Bhagani Sanjay R SR Klinker Hartwig H F HHF Rizzardini Giuliano G Girard Pierre-Marie PM Tural Cristina C Shulman Nancy S NS Mobashery Niloufar N Hu Yiran B YB Fredrick Linda M LM Pilot-Matias Tami T Trinh Roger R Gane Edward E
Open forum infectious diseases 20170722 3
<h4>Background</h4>Ombitasvir, paritaprevir with ritonavir, and dasabuvir (OBV/PTV/r ± DSV) ±ribavirin (RBV) are approved to treat hepatitis C virus (HCV) genotype 1 and 4 infection. Here, we investigate the safety and efficacy of OBV/PTV/r + DSV ±RBV for HCV genotype 1, and OBV/PTV/r + RBV for HCV genotype 4, in human immunodeficiency virus (HIV)-1 coinfected patients with or without compensated cirrhosis.<h4>Methods</h4>TURQUOISE-I, Part 2 is a phase 3 multicenter study. Patients with or witho ...[more]